108 Biocapital Growth Fund, LPFirm match from fund name (lower confidence)
108 BioCapital Growth Fund, LP
Open: first sale Oct 2025, per Form D (fund age approximates vintage)
- Vintage
- 2025
- Fund size
- $10.79M (Form D)
- Stages
- Not stated
- Sectors
- Biotech, Medical devices
- Regions
- US
01 · Thesis
108 BioCapital invests in innovative biotech and medtech companies addressing significant unmet medical needs, seeking transformative healthcare solutions that improve patient outcomes. The firm partners with visionary entrepreneurs and management teams to accelerate growth in diagnostics, therapeutic devices, and personalized medicine.Inferred from the firm's website
02 · Initial check
$108K to $180K (estimated from fund size)
Estimated from Form D
03 · Who to approach
Named on this fund's Form D
- Steve Ward, Chief Financial Officer
- Sasha Bakhru, Issuer's Co-Founder, Managing Partner & CEO
- Shom Jagtiani, General Partner
04 · Deals
No deals attributed to this fund yet.
05 · Evidence
Firm-wideAt 108 BioCapital, we are dedicated to advancing the frontiers of medical innovation.
Our mission is to invest in transformative healthcare solutions that address urgent unmet medical needs, improve patient outcomes, and deliver sustained value to our investors.
https://108.bio/about-us/
06 · Sources
Last verified: Oct 28, 2026